Alebund Pharmaceuticals (Jiangsu) Limited Class H · HKEX:9637

Alebund Pharmaceuticals (Jiangsu) Limited Class H financial statements

Alebund Pharmaceuticals (Jiangsu) Limited Class H's income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in CNY

Income statement

LineFY2025FY2024
Revenue30.6M6.53M
Cost of revenue17.1M4.14M
Gross profit13.4M2.38M
Research and development372.6M235.4M
Selling, general and administrative52.1M17.2M
Operating income-641.3M-306.9M
Depreciation and amortization44.7M12.5M
EBITDA-596.5M-294.4M
Interest expense110.5M29.4M
Income before tax-751.8M-335.1M
Net income-750.0M-326.0M
Earnings per share, basic-2.21-0.96

Balance sheet

LineFY2025FY2024
Cash and equivalents358.3M343.8M
Short-term investments172.8M22.3M
Receivables0865.0K
Inventory10.3M6.12M
Current assets558.7M388.8M
Total assets1.34B1.11B
Accounts payable67.8M25.9M
Current liabilities239.8M1.94B
Long-term debt545.3M445.3M
Total liabilities836.7M2.45B
Shareholders' equity503.2M-1.33B
Shares outstanding339.9M339.9M

Cash flow

LineFY2025FY2024
Cash from operations-287.9M-249.9M
Capital spending-101.6M-236.7M
Free cash flow-389.5M-486.6M
Change in cash17.0M280.4M